Stock Scorecard
Stock Summary for ABVC BioPharma Inc (ABVC) - $2.86 as of 9/17/2025 7:40:43 PM EST
Total Score
5 out of 30
Safety Score
15 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ABVC
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ABVC
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ABVC
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ABVC
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ABVC (15 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 2 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ABVC
Financial Details for ABVC
Company Overview |
|
|---|---|
| Ticker | ABVC |
| Company Name | ABVC BioPharma Inc |
| Country | USA |
| Description | ABVC Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development of innovative drugs and medical devices targeting unmet medical needs primarily in the United States. With a diverse pipeline that encompasses both therapeutic agents and delivery systems, ABVC is committed to advancing its research initiatives to improve patient outcomes across various disease indications. The company leverages cutting-edge technologies and strategic collaborations, positioning itself as a promising player in the biopharmaceutical landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 2.86 |
| Price 4 Years Ago | 33.90 |
| Last Day Price Updated | 9/17/2025 7:40:43 PM EST |
| Last Day Volume | 45,163 |
| Average Daily Volume | 124,803 |
| 52-Week High | 5.48 |
| 52-Week Low | 0.40 |
| Last Price to 52 Week Low | 615.00% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 21.46 |
| Sector PE | 40.64 |
| 5-Year Average PE | -36.35 |
| Free Cash Flow Ratio | 143.00 |
| Industry Free Cash Flow Ratio | 13.30 |
| Sector Free Cash Flow Ratio | 29.51 |
| Current Ratio Most Recent Quarter | 0.42 |
| Total Cash Per Share | 0.02 |
| Book Value Per Share Most Recent Quarter | 0.37 |
| Price to Book Ratio | 9.53 |
| Industry Price to Book Ratio | 29.01 |
| Sector Price to Book Ratio | 32.14 |
| Price to Sales Ratio Twelve Trailing Months | 170.89 |
| Industry Price to Sales Ratio Twelve Trailing Months | 42.18 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.15 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 23,541,800 |
| Market Capitalization | 67,329,548 |
| Institutional Ownership | 1.56% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 3.56% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 37.04% |
| Reported EPS 12 Trailing Months | -0.25 |
| Reported EPS Past Year | -0.62 |
| Reported EPS Prior Year | -1.95 |
| Net Income Twelve Trailing Months | -3,056,279 |
| Net Income Past Year | -4,903,000 |
| Net Income Prior Year | -7,788,000 |
| Quarterly Revenue Growth YOY | -9.20% |
| 5-Year Revenue Growth | -6.20% |
| Operating Margin Twelve Trailing Months | -1,021.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 388,251 |
| Total Cash Past Year | 248,382 |
| Total Cash Prior Year | 60,155 |
| Net Cash Position Most Recent Quarter | -611,749 |
| Net Cash Position Past Year | -751,618 |
| Long Term Debt Past Year | 1,000,000 |
| Long Term Debt Prior Year | 1,569,456 |
| Total Debt Most Recent Quarter | 1,000,000 |
| Equity to Debt Ratio Past Year | 0.55 |
| Equity to Debt Ratio Most Recent Quarter | 0.88 |
| Total Stockholder Equity Past Year | 1,226,140 |
| Total Stockholder Equity Prior Year | 8,388,050 |
| Total Stockholder Equity Most Recent Quarter | 7,013,635 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -1,755,900 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.07 |
| Free Cash Flow Past Year | -1,809,145 |
| Free Cash Flow Prior Year | -4,257,046 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.07 |
| MACD Signal | -0.05 |
| 20-Day Bollinger Lower Band | 0.88 |
| 20-Day Bollinger Middle Band | 2.48 |
| 20-Day Bollinger Upper Band | 4.08 |
| Beta | 0.27 |
| RSI | 48.39 |
| 50-Day SMA | 1.34 |
| 150-Day SMA | 2.64 |
| 200-Day SMA | 6.82 |
System |
|
| Modified | 9/17/2025 4:20:29 PM EST |